StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Viridian Therapeutic (VRDN) PT Raised to $31 at Goldman Sachs
September 12, 2024 5:07 AM
Goldman Sachs analyst Richard Law raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $31.00 (from $25.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Viridian Therapeutic (VRDN) PT Raised to $44 at RBC Capital
September 13, 2024 6:33 AM
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
September 11, 2024 11:25 PM
Viridian Therapeutic (VRDN) PT Raised to $38 at Needham
September 11, 2024 7:11 AM
H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)
September 11, 2024 6:37 AM
Viridian Therapeutic (VRDN) PT Raised to $22 at B.Riley
September 11, 2024 6:24 AM
After-hours movers: GameStop, Dave & Buster's, Viridian Therapeutics
September 10, 2024 4:33 PM
Form 424B5 Viridian Therapeutics,
September 10, 2024 4:28 PM
Viridian Therapeutics (VRDN) Announces Proposed $150M Share and Warrant Offering
September 10, 2024 4:01 PM
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
September 10, 2024 4:01 PM
Viridian Therapeutic (VRDN) PT Raised to $40 at Stifel
September 10, 2024 1:08 PM
Viridian Therapeutic (VRDN) PT Raised to $56 at BTIG
September 10, 2024 11:41 AM
Form 8-K Viridian Therapeutics, For: Sep 10
September 10, 2024 7:11 AM
Viridian Therapeutics (VRDN) Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
September 10, 2024 7:02 AM
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
September 10, 2024 7:00 AM
